Logo Image
|Articles|March 9, 2016

BioPhorum Operations Group Invites Industry Stakeholders to Participate in Technology Roadmap

The group is inviting additional industry stakeholders to participate in the technology roadmapping process to address complexity of the current industry structure, which the group says has held back innovation.

The BioPhorum Operations Group is inviting industry stakeholders including academics, supply partner R&D heads, regulators, and regional hubs to participate in the group’s Technology Roadmap for the future of biopharmaceuticals. The Technology Roadmap is being developed in response to the complexity of the current industry structure, which the group says has held back innovation with many end users trying to develop new technologies in isolation, and resulting in suppliers having to guess end user requirements. The group currently has more than 100 active participants in the roadmapping process, consisting of a steering committee and six teams working to address key technology challenges.

Eighteen BioPhorum member companies are currently developing the roadmap, and the group is hoping to add additional participants to the project. When complete, the Technology Roadmap will be available for free and updated and published on a regular basis. 

Source: BioPhorum Operations Group

Related to this article

View more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more